drugset / Trial / NCT00157573
GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer
Phase 2
Completed
72 enrolled
Massachusetts General Hospital
Bayer · collabDana-Farber Cancer Institute · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
Granulocyte macrophage colony-stimulating factor (GM-CSF) is an immunostimulant and preliminary data suggests it may change the natural history of prostate cancer and melanoma. This study looks at ability of GM-CSF to alter disease progression in women who have recurrent but asymptomatic recurrence of their ovarian cancer.
Timeline
- Start
- 2004-12
- Primary completion
- 2008-10
- Completion
- 2010-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sargramostim | Protein / enzyme biologic | 150 ug/m2 | Subcutaneous |
| Subject | sargramostim | Protein / enzyme biologic | 250 ug/m2 | Subcutaneous |